ICON (ICLR) vs Insight Molecular Diagnostics (IMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Insight Molecular Diagnostics (IMDX) has outperformed ICON (ICLR) over the past year, losing 10.9% versus a loss of 11.8%. Over five years, ICLR leads with a -40.2% price change compared with -95.2% for IMDX. ICON is the larger company by market cap ($12.69 billion vs $107.3 million), about 118.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ICLR | IMDX |
|---|---|---|
| Share price | $164.50 | $3.28 |
| Market cap | $12.69B | $107.34M |
| 1-day change | +0.26% | -5.20% |
| YTD return | -9.72% | -56.27% |
| 1-year return | -11.79% | -10.87% |
| 5-year return | -40.19% | -95.18% |
| P/E ratio (TTM) | 173.16 | — |
| Forward P/E | 13.93 | — |
| EPS (TTM) | $0.95 | $-1.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $8.25B | — |
| Revenue growth (YoY) | +0.76% | — |
| Net income (latest FY) | $229.34M | — |
| Gross margin | 26.37% | — |
| Operating margin | 5.37% | — |
| Net margin | 2.78% | — |
| 52-week high | $203.91 | $8.51 |
| 52-week low | $66.57 | $2.42 |
| Distance from 52-week high | -19.33% | -61.46% |
| Analyst consensus | buy | none |
| Avg. price target upside | +12.10% | +151.52% |
| Average volume | 822.57K | 232.87K |
| Shares outstanding | 77.15M | 32.72M |
| Employees | 40,200 | 55 |
| Sector | Healthcare | Healthcare |
| Industry | Diagnostics & Research | Diagnostics & Research |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ICON is about 118.2 times larger than Insight Molecular Diagnostics by market value ($12.69B vs $107.34M).
About ICON
ICLR stock →ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Healthcare · Diagnostics & Research · 40,200 employees
About Insight Molecular Diagnostics
IMDX stock →Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally.
Healthcare · Diagnostics & Research · 55 employees
ICLR vs IMDX FAQ
Which is bigger, ICON or Insight Molecular Diagnostics?
ICON (ICLR) is larger, with a market capitalization of $12.69B compared with $107.34M for Insight Molecular Diagnostics (IMDX).
Which stock has performed better over the past year, ICLR or IMDX?
IMDX returned -10.87% over the past 12 months, compared with -11.79% for ICLR (price return, excluding dividends). Past performance does not predict future results.
Are ICON and Insight Molecular Diagnostics in the same industry?
Yes. Both are classified in the Diagnostics & Research industry within the Healthcare sector.